Shield Therapeutics PLC Notice of Results (5234Q)
29 Junio 2022 - 01:00AM
UK Regulatory
TIDMSTX
RNS Number : 5234Q
Shield Therapeutics PLC
29 June 2022
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Notice of Results
Analyst and Investor Briefings
London, UK, 29 June 2022: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with an initial focus on
addressing iron deficiency, will announce its final results for the
year ended 31 December 2021 on Thursday 30 June 2022.
Analyst briefing
A briefing open to analysts will take place remotely via Zoom on
Thursday 30 June 2022 at 13.30 (BST). If you would like the details
of this call, please contact Walbrook PR on shield@walbrookpr.com
.
Investor Briefing
CEO, Greg Madison, CFO, Hans-Peter Rudolf, and CMO, José Menoyo
MD, will also be hosting a live online presentation relating to the
final results via the Investor Meet Company platform at 16.30 (BST)
on Thursday 30 June. The presentation is open to all existing and
potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Investors who already follow Shield on the Investor Meet Company
platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards and
via the Company's website.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice
Lane/Nigel Birks +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Paul McManus/Lianne Applegarth/Alice +44 (0)20 7933 8780 or shield@walbrookpr.com
Woodings
Investor Contact (US Advisor) +1 617 429 3548 or jmullaly@lifesciadvisors.com
LifeSci Advisors, LLC
John Mullaly
About Accrufer(R) /Feraccru(R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
absorption compared to other oral iron therapies and has been shown
to be an efficacious and well-tolerated therapy in a range of
clinical trials. More information about Accrufer(R)/Feraccru(R),
including the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched
Accrufer(R) in the US and Feraccru(R) is commercialized in the UK
and European Union by Norgine B.V., who also have the marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of Accrufer(R) /
Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. in the Republic of Korea, and with KYE
Pharmaceuticals Inc. in Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBUGDLRDDDGDI
(END) Dow Jones Newswires
June 29, 2022 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024